This landmark Lancet study used propensity-score matching to compare TKR and UKR across 101,330 patients from the National Joint Registry for England and Wales. Unlike prior registry reports that compared unmatched populations, this study accounts for confounding by indication and reports mortality, complications, readmission, and length of stay — not just revision. The central question: when you control for patient selection, does the higher UKR revision rate outweigh its perioperative advantages?
Revision rate was long treated as the dominant metric in knee arthroplasty selection — and by that measure alone, UKR looks inferior. This paper forces a reckoning: when you match patients properly and count deaths, strokes, MIs, and blood transfusions, TKR carries a substantially higher burden of serious harm.
When counseling a patient who is eligible for either procedure, present the full trade-off: UKR offers lower mortality risk, fewer major complications, shorter hospital stay, and easier revision if it fails — at the cost of a higher reoperation rate over time.
For the right patient (medial compartment OA, intact ACL, correctable deformity), defaulting to TKR because of revision statistics alone is not evidence-based practice. One nuance worth knowing: UKR revision rate is volume-dependent. Surgeons who perform more UKRs annually have lower revision rates — so both patient selection and surgical experience matter when interpreting registry data.
This landmark Lancet study used propensity-score matching to compare TKR and UKR across 101,330 patients from the National Joint Registry for England and Wales. Unlike prior registry reports that compared unmatched populations, this study accounts for confounding by indication and reports mortality, complications, readmission, and length of stay — not just revision. The central question: when you control for patient selection, does the higher UKR revision rate outweigh its perioperative advantages?
Revision rate was long treated as the dominant metric in knee arthroplasty selection — and by that measure alone, UKR looks inferior. This paper forces a reckoning: when you match patients properly and count deaths, strokes, MIs, and blood transfusions, TKR carries a substantially higher burden of serious harm.
When counseling a patient who is eligible for either procedure, present the full trade-off: UKR offers lower mortality risk, fewer major complications, shorter hospital stay, and easier revision if it fails — at the cost of a higher reoperation rate over time.
For the right patient (medial compartment OA, intact ACL, correctable deformity), defaulting to TKR because of revision statistics alone is not evidence-based practice. One nuance worth knowing: UKR revision rate is volume-dependent. Surgeons who perform more UKRs annually have lower revision rates — so both patient selection and surgical experience matter when interpreting registry data.